New determinates of disease progression and outcome in metastatic ovarian carcinoma

Histology and Histopathology

Volumn 25, Issue 12, 2010, Pages 1591-1609

  Davidson, Ben ^a,b   Reich, Reuven ^c   Trope, Claes G ^b,d   Wang, Tian Li ^e   Shih, Ie Ming ^f  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e Departments of Gynecology and Oncology   (United States)

^f DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Chemotherapy; Effusion; Metastasis; Ovarian carcinoma; Prognosis; Tumor progression

Indexed keywords

TUMOR MARKER;

ASCITES FLUID; CARCINOMA; DISEASE COURSE; FEMALE; HUMAN; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PLEURA EFFUSION; REVIEW;

ASCITIC FLUID; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; OVARIAN NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; TUMOR MARKERS, BIOLOGICAL;

EID: 79952197556     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (205)

1. Abedini M.R., Qiu Q., Yan X. and Tsang B.K. (2004). Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23, 6997-7004.
2. Agarwal R. and Kaye S.B. (2003). Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516.
3. Aigner K., Dampier B., Descovich L., Mikula M., Sultan A., Schreiber M., Mikulits W., Brabletz T., Strand D., Obrist P., Sommergruber W., Schweifer N., Wernitznig A., Beug H., Foisner R. and Eger A. (2007). The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. Oncogene 2, 6979-6988.
4. Akahira J.I., Yoshikawa H., Shimizu Y., Tsunematsu R., Hirakawa T., Kuramoto H., Shiromizu K., Kuzuya K., Kamura T., Kikuchi Y., Kodama S., Yamamoto K. and Sato S. (2001). Prognostic factors of stage IV epithelial ovarian cancer: A multicenter retrospective study. Gynecol. Oncol. 81, 398-403.
5. Altieri D.C. (2003). Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22, 8581-8589.
6. Altomare D.A., Wang H.Q., Skele K.L., De Rienzo A., Klein-Szanto A.J., Godwin A.K. and Testa J.R. (2004). AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853-5857.
7. Annunziata C.M., Tuft Stavnes H., Kleinberg L., Berner A., Hernandez L.F., Birrer M.J., Steinberg S.M., Davidson B. and Kohn E.C. (2010). NF-NB transcription factors are co-expressed and convey poor outcome in ovarian cancer. Cancer 116, 3276-3284.
8. Arboleda M.J., Lyons J.F., Kabbinavar F.F., Bray M.R., Snow B.E., Ayala R., Danino M., Karlan B.Y. and Slamon D.J. (2003). Overexpression of AKT2/protein kinase Bß leads to up-regulation of ß1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63, 196-206.
9. Ashkenazi A. (2002). Targeting death and decoy receptors of the tumornecrosis factor superfamily. Nat. Rev. Cancer 2, 420-430.
10. Bach L.A., Headey S.J. and Norton R.S. (2005). IGF-binding proteins--the pieces are falling into place. Trends Endocrinol. Metab. 16, 228-234.
11. Barrena Medel N.I., Wright J.D. and Herzog T.J. (2010). Targeted therapies in epithelial ovarian cancer. J. Oncol. 2010, 314326.
12. Bassères D.S. and Baldwin A.S. (2006). Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25, 6817-6830.
13. Batlle E., Sancho E., Francí C., Domínguez D., Monfar M., Baulida J. and García De Herreros A. (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84-89.
14. Beauchamp M.C., Yasmeen A., Knafo A. and Gotlieb W.H. (2010). Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J. Oncol. 2010, 257058.
15. Bellacosa A., de Feo D., Godwin A.K., Bell D.W., Cheng J.Q., Altomare D.A., Wan M., Dubeau L., Scambia G., Masciullo V., Ferrandina G., Benedetti Panici P., Mancuso S., Neri G. and Testa J.R. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280-285.
16. Bellacosa A., Kumar C.C., Di Cristofano A. and Testa J.R. (2005). Activation of AKT kinases in cancer: Implications for therapeutic targeting. Adv. Cancer Res. 94, 29-86.
17. Bendoraite A., Knouf E.C., Garg K.S., Parkin R.K., Kroh E.M., O'Briant K.C., Ventura A.P., Godwin A.K., Karlan B.Y., Drescher C.W., Urban N., Knudsen B.S. and Tewari M. (2010). Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol. Oncol. 116, 117-125.
18. Bignotti E., Tassi R.A., Calza S., Ravaggi A., Romani C., Rossi E., Falchetti M., Odicino F.E., Pecorelli S. and Santin A.D. (2006). Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 103, 405-416.
19. Blagden S. and Gabra H. (2009). Promising molecular targets in ovarian cancer. Curr. Opin. Oncol. 21, 412-419.
20. Blechschmidt K., Sassen S., Schmalfeldt B., Schuster T., Höfler H. and Becker K.F. (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br. J. Cancer 98, 489-495.
21. Bokoch G.M. (2003). Biology of the p21-activated kinases. Annu. Rev. Biochem. 72, 743-781.
22. Bolós V., Peinado H., Pérez-Moreno M.A., Fraga M.F., Esteller M. and Cano A. (2003). The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116, 499-511.
23. Bonnefoi H., A'Hern R.P., Fisher C., Macfarlane V., Barton D., Blake P., Shepherd J.H. and Gore M.E. (1999). Natural history of stage IV epithelial ovarian cancer. J. Clin. Oncol. 17, 765-775.
24. Bunkholt Elstrand M., Dong H.P., Ødegaard E., Holth A., Elloul S., Reich R., Tropé C.G. and Davidson B. (2010). Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma. Hum. Pathol. 41, 794-804.
25. Campos S.M. and Ghosh S. (2010). A current review of targeted therapeutics for ovarian cancer. J. Oncol. 2010, 149362.
26. Cannistra S.A. (2004). Cancer of the ovary. N. Engl. J. Med. 351, 2519-2529.
27. Cano A., Pérez-Moreno M.A., Rodrigo I., Locascio A., Blanco M.J., del Barrio M.G., Portillo F. and Nieto M.A. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2, 76-83.
28. Castellvi J., Garcia A., Rojo F., Ruiz-Marcellan C., Gil A., Baselga J. and Ramon y Cajal S. (2006). Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107, 1801-1811.
29. Cavallaro U. and Christofori G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118-132.
30. Chen C., Edelstein L.C. and Gélinas C. (2000). The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bclx(L). Mol. Cell Biol. 20, 2687-2695.
31. Chen R., Alvero A.B., Silasi D.A., Kelly M.G., Fest S., Visintin I., Leiser A., Schwartz P.E., Rutherford T. and Mor G. (2008). Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 27, 4712-4723.
32. Choi Y.L., Kim J., Kwon M.J., Choi J.S., Kim T.J., Bae D.S., Koh S.S., In Y.H., Park Y.W., Kim S.H., Ahn G. and Shin Y.K. (2007). Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol. Histopathol. 22, 1185-1195.
33. Chow L.M. and Baker S.J. (2006). PTEN function in normal and neoplastic growth. Cancer Lett. 241, 184-196.
34. Chu Z.L., Mckinsey T.A., Liu L., Gentry J.J., Malim M.H. and Ballard D.W. (1997). Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-IAP2 is under NF-kappaB control. Proc. Natl. Acad. Sci. USA 94, 10057-10062.
35. Comijn J., Berx G., Vermassen P., Verschueren K., van Grunsven L., Bruyneel E., Mareel M., Huylebroeck D. and van Roy F. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates Ecadherin and induces invasion. Mol. Cell 7, 1267-1278.
36. Cormio G., Maneo A., Parma G., Pittelli M.R., Miceli M.D. and Bonazzi C. (1995). Central nervous system metastases in patients with ovarian carcinoma. A report of 23 cases and literature review. Ann. Oncol. 6, 571-574.
37. Cully M., You H., Levine A.J. and Mak T.W. (2006). Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 6, 184-192.
38. Curtin J.P., Malik R., Venkatraman E.S., Barakat R.R. and Hoskins W.J. (1997). Stage IV ovarian cancer: impact of surgical debulking. Gynecol. Oncol. 64, 9-12.
39. Darzynkiewicz Z., Juan G., Li X., Gorczyca W., Murakami T. and Traganos F. (1997). Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27, 1-20.
40. Darzynkiewicz Z., Bedner E. and Traganos F. (2001). Difficulties and pitfalls in analysis of apoptosis. Methods Cell. Biol. 63, 527-546.
41. Davidson B. (2004). Malignant effusions: from diagnosis to biology. Diagn. Cytopathol. 31, 246-254.
42. Davidson B. (2007). The biological characteristics of cancers involving the serosal cavities. Crit. Rev. Oncog. 13, 189-227.
43. Davidson B., Berner A., Nesland J.M., Risberg B., Berner H.S., Tropé C.G., Kristensen G.B., Bryne M. and Flørenes V.A. (2000). Ecadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J. Pathol. 192, 460-469.
44. Davidson B., Reich R., Lazarovici P., Nesland J.M., Risberg B., Tropé C.G. and Flørenes V.A. (2003). Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin. Cancer Res. 9, 2248-2259.
45. Davidson B., Zhang Z., Kleinberg L., Li M., Flørenes V.A., Wang T.L. and Shihle.M. (2006a). Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res. 12, 5944-5950.
46. Davidson B., Espina V., Flørenes V.A., Liotta L.A., Kristensen G.B., Tropé C.G., Berner A. and Kohn E.C. (2006b) Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome. Clin. Cancer Res. 12, 791-799.
47. Davidson B., Shih I.M. and Wang T.L. (2008a). Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. Hum. Pathol. 39, 1630-1636.
48. Davidson B., Hadar R., Schlossberg A., Sternlicht T., Slipicevic A., Skrede M., Risberg B., Flørenes V.A., Kopolovic J. and Reich R. (2008b). Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum. Pathol. 39, 87-95.
49. Denley A., Cosgrove L.J., Booker G.W., Wallace J.C. and Forbes B.E. (2005). Molecular interactions of the IGF system. Cytokine Growth Factor Rev. 16, 421-439.
50. Dong H.P., Kleinberg L., Silins I., Flørenes V.A., Trope' C.G., Risberg B., Nesland J.M. and Davidson B. (2008a). Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer 112, 84-93.
51. Dong H.P., Kleinberg L., Davidson B. and Risberg B. (2008b). Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat. Protoc. 3, 955-964.
52. Dong H.P., Holth A., Kleinberg L., Ruud M.G., Elstrand M.B., Tropé C.G., Davidson B. and Risberg B. (2009). Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the Annexin-V/7-AAD assay-Clinical relevance and comparison to other apoptosis parameters. Am. J. Clin. Pathol. 132, 756-762.
53. Elenbaas B. and Weinberg R.A. (2001). Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169-184.
54. Elloul S., Elstrand M.B., Nesland J.M., Tropé C.G., Kvalheim G., Goldberg I., Reich R. and Davidson B. (2005). Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 103, 1631-1643.
55. Elloul S., Silins I., Tropé C.G., Benshushan A., Davidson B. and Reich R. (2006). Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch. 449, 520-528.
56. Elloul S., Vaksman O., Tuft Stavnes H., Tropé C.G., Davidson B. and Reich R. (2010). Mesenchymal-to-Epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin. Exp. Metastasis 27, 161-172.
57. Feldman G.B., Knapp R.C., Order S.E. and Hellman S. (1972). The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res. 32, 1663-1666.
58. Firth S.M. and Baxter R.C. (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 23, 824-854.
59. González-Mariscal L., Betanzos A., Nava P. and Jaramillo B.E. (2003) Tight junction proteins. Prog. Biophys. Mol. Biol. 81, 1-44.
60. Gotzmann J., Mikula M., Eger A., Schulte-Hermann R., Foisner R., Beug H. and Mikulits W. (2004). Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat. Res. 566, 9-20.
61. Guertin D.A. and Sabatini D.M. (2007). Defining the role of mTOR in cancer. Cancer Cell 12, 9-22.
62. Guicciardi M.E., Leist M. and Gores G.J. (2004). Lysosomes in cell death. Oncogene 23, 2881-2890.
63. Guo R.X., Qiao Y.H., Zhou Y., Li L.X., Shi H.R. and Chen K.S. (2008). Increased staining for phosphorylated AKT and nuclear factorkappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol. Int. 58, 749-756.
64. Guvakova M.A. (2007). Insulin-like growth factors control cell migration in health and disease. Int. J. Biochem. Cell Biol. 39, 890-909.
65. Hajra K.M., Chen D.Y. and Fearon E.R. (2002). The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 62, 1613-1618.
66. Hanahan D. and Weinberg R.A. (2000) The hallmarks of cancer. Cell 100, 57-70.
67. Heinzelmann-Schwarz V.A., Gardiner-Garden M., Henshall S.M., Scurry J., Scolyer R.A., Davies M.J., Heinzelmann M., Kalish L.H., Bali A., Kench J.G., Edwards L.S., Vanden Bergh P.M., Hacker N.F., Sutherland R.L. and O'Brien P.M. (2004). Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 10, 4427-4436.
68. Hernandez L., Hsu S., Davidson B., Birrer M.J., Kohn E.C. and Annunziata C.M. (2010). Activation of NF-AB signaling by IKKb increases aggressiveness of ovarian cancer. Cancer Res. 70, 405-414.
69. Hewitt K.J., Agarwal R. and Morin P.J. (2006). The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6, 186.
70. Hibbs K., Skubitz K.M., Pambuccian S.E., Casey R.C., Burleson K.M., Oegema T.R. Jr, Thiele J.J., Grindle S.M., Bliss R.L. and Skubitz A.P. (2004). Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165, 397-414.
71. Hirabayashi K. and Graham J. (1970). The genesis of ascites in ovarian cancer. Am. J. Obstet. Gynecol. 106, 492-497.
72. Hofer-Warbinek R., Schmid J.A., Stehlik C., Binder B.R., Lipp J. and de Martin R. (2000). Activation of NF-kappa B by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J. Biol. Chem. 275, 22064-22068.
73. Holschneider C.H. and Berek J.S. (2000). Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19, 3-10.
74. Hosono S., Kajiyama H., Terauchi M., Shibata K., Ino K., Nawa A. and Kikkawa F. (2007). Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br. J. Cancer 96, 314-320.
75. Hough C.D., Sherman-Baust C.A., Pizer E.S., Montz F.J., Im D.D., Rosenshein N.B., Cho K.R., Riggins G.J. and Morin P.J. (2000). Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 60, 6281-6287.
76. Hough C.D., Cho K.R., Zonderman A.B., Schwartz D.R. and Morin P.J. (2001). Coordinately up-regulated genes in ovarian cancer. Cancer Res. 61, 3869-3876.
77. Hu L., Hofmann J., Lu Y., Mills G.B. and Jaffe R.B. (2002). Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087-1092.
78. Huynh H., Teo C.C. and Soo K.C. (2007). Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Mol. Cancer Ther. 6, 2959-2966.
79. Igney F.H. and Krammer P.H. (2002) Death and anti-death: tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277-288.
80. Ikenouchi J., Matsuda M., Furuse M. and Tsukita S. (2003). Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J. Cell Sci. 116, 1959-1967.
81. Imai T., Horiuchi A., Wang C., Oka K., Ohira S., Nikaido T. and Konishi I. (2003). Hypoxia attenuates the expression of E-cadherin via upregulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 163, 1437-1447.
82. Imamura R., Konaka K., Matsumoto N., Hasegawa M., Fukui M., Mukaida N., Kinoshita T. and Suda T. (2004). Fas ligand induces cell-autonomous NF-cB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-m. J. Biol. Chem. 279, 46415-46423.
83. Jemal A., Siegel R., Ward E., Hao Y., Xu J. and Thun M.J. (2009). Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
84. Jiao W., Miyazaki K. and Kitajima Y. (2002) Inverse correlation between E-cadherin and Snail expression in hepatocellular carcinoma cell lines in vitro and in vivo. Br. J. Cancer 86, 98-101.
85. Jin H., Yu Y., Zhang T., Zhou X., Zhou J., Jia L., Wu Y., Zhou B.P. and Feng Y. (2010). Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int. J. Cancer 126, 2102-2111.
86. Johnstone R.W., Ruefli A.A. and Lowe S.W. (2002). Apoptosis: A link between cancer genetics and chemotherapy. Cell 108, 153-164.
87. Kalli K.R., Oberg A.L., Keeney G.L., Christianson T.J., Low P.S., Knutson K.L. and Hartmann L.C. (2008). Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol. Oncol. 108, 619-626.
88. Katsaros D., Yu H., Levesque M.A., Danese S., Genta F., Richiardi G., Fracchioli S., Khosravi M.J., Diamandi A., Gordini G., Diamandis E.P. and Massobrio M. (2001). IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival. Eur. J. Cancer 37, 478-485.
89. Kaufmann S.H., Lee S.H., Meng X.W., Loegering D.A., Kottke T.J., Henzing A.J., Ruchaud S., Samejima K. and Earnshaw W.C. (2008). Apoptosis-associated caspase activation assays. Methods 44, 262-272.
90. Kelemen L.E. (2006). The role of folate receptor nnin cancer development, progression and treatment: Cause, consequence or innocent bystander? Int. J. Cancer 119, 243-250.
91. Kerr J.F., Wyllie A.H. and Currie A.R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26, 239-257.
92. Kim K., Visintin I., Alvero A.B. and Mor G. (2009). Development and validation of a protein-based signature for the detection of ovarian cancer. Clin. Lab. Med. 29, 47-55.
93. Kim R.H., Peters M., Jang Y., Shi W., Pintilie M., Fletcher G.C., DeLuca C., Liepa J., Zhou L., Snow B., Binari R.C., Manoukian A.S., Bray M.R., Liu F.F., Tsao M.S. and Mak T.W. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263-273.
94. Kleinberg L., Holth A., Fridman E., Schwartz I., Shih I-M. and Davidson B. (2007a). The diagnostic role of claudins in serous effusions. Am. J. Clin. Pathol. 127, 928-937.
95. Kleinberg L., Flørenes V.A., Silins I., Haug K., Trope' C.G., Nesland J.M. and Davidson B. (2007b). Nuclear expression of Survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer 109, 228-238.
96. Kleinberg L., Holth A., Trope' C.G., Reich R. and Davidson B. (2008). Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum. Pathol. 39, 747-757.
97. Kleinberg L., Dong H.P., Holth A., Risberg B., Trope' C.G., Nesland J.M., Flørenes V.A. and Davidson B. (2009). Cleaved caspases and NF-NB p65 are prognostic factors in metastatic ovarian carcinoma. Hum. Pathol. 40, 795-806.
98. Kuo K.T., Mao T.L., Jones S., Veras E., Ayhan A., Wang T.L., Glas R., Slamon D., Velculescu V.E., Kuman R.J. and Shih I-M. (2009). Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 174, 1597-1601.
99. Kurrey N.K., and Bapat S.A. (2005). Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol. Oncol. 97, 155-165.
100. Lee Y.K. and Park N.H. (2009). Prognostic value and clinicopathological significance of p53 and PTEN in epithelial ovarian cancers. Gynecol. Oncol. 112, 475-480.
101. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C. and Altieri DC. (1998). Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396, 580-584.
102. Li J., Sherman-Baust C.A., Tsai-Turton M., Bristow R.E., Roden R.B. and Morin P.J. (2009). Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9, 244.
103. Liston P., Fong W.G. and Korneluk R.G. (2003). The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22, 8568-8580.
104. Liu G.H., Wang S.R., Wang B. and Kong B.H. (2006). Inhibition of nuclear factor-kappaB by an antioxidant enhances paclitaxel sensitivity in ovarian carcinoma cell line. Int. J. Gynecol. Cancer 16, 1777-1782.
105. Liu J.R., Opipari A.W., Tan L., Jiang Y., Zhang Y., Tang H. and Nuñez G. (2002). Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 62, 924-931.
106. Lowe S.W. and Lin A.W. (2000). Apoptosis in cancer. Carcinogenesis 21, 485-495.
107. Lu K.H., Patterson A. P, Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., Ramoth L.R., Rosen D.G., Liu J., Hellstrom I., Smith D., Hartmann L., Fishman D., Berchuck A., Schmandt R., Whitaker R., Gershenson D.M., Mills G.B. and Bast R.C. Jr (2004). Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10, 3291-3300.
108. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Risch H.A., Puopolo M. and Yu H. (2006). The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin. Cancer Res. 12, 1208-1214.
109. Madrid L.V., Wang C.Y., Guttridge D.C., Schottelius A.J., Baldwin A.S. Jr and Mayo M.W. (2000). Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-kappaB. Mol. Cell Biol. 20, 1626-1638.
110. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T., Kimura A., Ohta T., Saito M., Kawagoe J., Takahashi K., Yada-Hashimoto N., Sakata M., Motoyama T., Kurachi H., Tasaka K. and Murata Y. (2004). Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 279, 23477-23485.
111. Mabuchi S., Ohmichi M., Nishio Y., Hayasaka T, Kimura A., Ohta T., Kawagoe J., Takahashi K., Yada-Hashimoto N., Seino-Noda H., Sakata M., Motoyama T., Kurachi H., Testa J.R., Tasaka K. and Murata Y. (2004). Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin. Cancer Res. 10, 7645-7654.
112. Mabuchi S., Altomare D.A., Cheung M., Zhang L., Poulikakos P.I., Hensley H.H., Schilder R.J., Ozols R.F. and Testa J.R. (2007). RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin. Cancer Res. 13, 4261-4270.
113. Maddika S., Ande S.R., Panigrahi S., Paranjothy T., Weglarczyk K., Zuse A., Eshraghi M., Manda K.D., Wiechec E. and Los M. (2007). Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist. Updat. 10, 13-29.
114. Manser E., Leung T., Salihuddin H., Shao Z.S. and Lim L. (1994). A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 367, 40-46.
115. Miyoshi A., Kitajima Y., Kido S. Shimonishi T., Matsuyama S., Kitahara K. and Miyazaki K. (2005). Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. Br. J. Cancer 92, 252-258.
116. Morel J., Audo R., Hahne M. and Combe B. (2005). Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J. Biol. Chem. 280, 15709-15718.
117. Morin P.J. (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 65, 9603-9606.
118. Morita K., Furuse M., Fujimoto K. and Tsukita S. (1999). Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 96, 511-516.
119. Nagy J.A., Masse E.M., Herzberg K.T., Meyers M.S., Yeo K.T., Yeo T.K., Sioussat T.M. and Dvorak H.F. (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites tumor accumulation. Cancer Res. 55, 360-368.
120. Neumann M. and Naumann M. (2007). Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J. 21, 2642-2654.
121. Norbury C.J. and Zhivotovsky B. (2004). DNA damage-induced apoptosis. Oncogene 23, 2797-2808.
122. Noske A., Lindenberg J.L., Darb-Esfahani S., Weichert W., Buckendahl A.C., Röske A., Sehouli J., Dietel M. and Denkert C. (2008). Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol. Rep. 20, 1409-1417.
123. Oda Y., Ohishi Y., Basaki Y., Kobayashi H., Hirakawa T., Wake N., Ono M., Nishio K., Kuwano M. and Tsuneyoshi M. (2007). Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci. 98, 1020-1026.
124. Orrenius S., Zhivotovsky B. and Nicotera P. (2003). Regulation of cell death: The calcium apoptosis link. Nat. Rev. Mol. Cell Biol. 4, 552-565.
125. Otsuki Y., Li Z. and Shibata M.A. (2003). Apoptotic detection methods--from morphology to gene. Prog. Histochem. Cytochem. 38, 275-339.
126. Page C., Lin H.J., Jin Y., Castle V.P., Nunez G., Huang M. and Lin J. (2000). Overexpression of Akt/AKT can modulate chemotherapyinduced apoptosis. Anticancer Res. 20, 407-416.
127. Pahl H.L. (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866.
128. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S. and Leamon C.P. (2005). Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 338, 284-293
129. Pecina-Slaus N. (2003). Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 3, 17.
130. Perkins N.D. (2007). Integrating cell-signalling pathways with NFkappaB and IKK function. Nat. Rev. Mol. Cell Biol. 8, 49-62.
131. Perkins N.D. and Gilmore T.D. (2006). Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 13, 759-772.
132. Pianetti S., Arsura M., Romieu-Mourez R., Coffey R.J. and Sonenshein GE. (2001). Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20, 1287-1299.
133. Pon Y.L., Zhou H.Y., Cheung A.N., Ngan H.Y. and Wong A.S. (2008). p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 68, 6524-6532.
134. Poser I., Domínguez D., de Herreros A.G., Varnai A., Buettner R. and Bosserhoff A.K. (2001). Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J. Biol. Chem. 276, 24661-24666.
135. Pozarowski P., Grabarek J. and Darzynkiewicz Z. (2004). Flow cytometry of apoptosis. Curr. Protoc. Cell Biol. Chapter 18, Unit 18.8.
136. Rangel L.B., Agarwal R., D'Souza T., Pizer E.S., Alò P.L., Lancaster W.D., Gregoire L., Schwartz D.R., Cho K.R. and Morin P.J. (2003). Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin. Cancer Res. 9, 2567-2575.
137. Reed J.C. (2006). Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat. Clin. Pract. Oncol. 3, 388-398.
138. Riedl S.J. and Shi Y. (2004). Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev. Mol. Cell Biol. 5, 897-907.
139. Romani C., Comper F., Bandiera E., Ravaggi A., Bignotti E., Tassi R.A., Pecorelli S. and Santin A.D. (2009). Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am. J. Obstet. Gynecol. 201, 70. e1-9.
140. Rosivatz E., Becker I., Specht K. Fricke E., Luber B., Busch R., Höfler H. and Becker K.F. (2002). Differential expression of the epithelialmesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol. 161, 1881-1891.
141. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S. and Reed J.C. (1997). The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16, 6914-6925.
142. Sanna M.G., da Silva Correia J., Ducrey O., Lee J., Nomoto K., Schrantz N., Deveraux Q.L. and Ulevitch R.J. (2002). IAP suppression of apoptosis involves distinct mechanisms: the TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell Biol. 22, 1754-1766.
143. Sachdev D. and Yee D. (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol. Cancer Ther. 6, 1-12.
144. Saeki R., Kondoh M., Kakutani H., Tsunoda S., Mochizuki Y., Hamakubo T., Tsutsumi Y., Horiguchi Y. and Yagi K. (2009). A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol. Pharmacol. 76, 918-926.
145. Sakai K., Kamura T., Hirakawa T., Saito T., Kaku T. and Nakano H. (1997). Relationship between pelvic lymph node involvement and other disease sites in patients with ovarian cancer. Gynecol. Oncol. 65, 164-168.
146. Salazar M.D. and Ratnam M. (2007). The folate receptor: What does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 26, 141-152.
147. Samanta A.K., Huang H.J., Le X.F., Mao W., Lu K.H., Bast R.C. Jr and Liao W.S. (2009). MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer 115, 3897-3908.
148. Santin A.D., Zhan F., Bellone S., Palmieri M., Cane S., Bignotti E., Anfossi S., Gokden M., Dunn D., Roman J.J., O'Brien T.J., Tian E., Cannon M.J., Shaughnessy J. Jr and Pecorelli S. (2004). Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112, 14-25.
149. Sarbassov D.D., Guertin D.A., Ali S.M. and Sabatini D.M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
150. Sayer R.A., Lancaster J.M., Pittman J., Gray J., Whitaker R., Marks J.R. and Berchuck A. (2005). High insulin-like growth factor-2 (IGF-2) gene expression is an independent predictor of poor survival for patients with advanced stage serous epithelial ovarian cancer. Gynecol. Oncol. 96, 355-361.
151. Schimmer A.D. (2004). Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64, 7183-7190.
152. Secchiero P., Gonelli A., Carnevale E., Milani D., Pandolfi A., Zella D. and Zauli G. (2003). TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation 107, 2250-2256.
153. Sethi G., Sung B. and Aggarwal B.B. (2008). Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 233, 21-31.
154. Shihle M., Sheu J.J., Santillan A., Nakayama K., Yen M.J., Bristow R.E., Vang R., Parmigiani G., Kurman R.J., Trope C.G., Davidson B. and Wang T.L. (2005). Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc. Natl. Acad. Sci. USA 102, 14004-14009.
155. Shih I-M. and Davidson B. (2009). Tumor-associated genes in ovarian cancer. Future Oncol. 5, 1641-1657.
156. Siu M.K., Wong E.S., Chan H.Y., Kong D.S., Woo N.W., Tam K.F., Ngan H.Y., Chan Q.K., Chan D.C., Chan K.Y. and Cheung A.N. (2010). Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int. J. Cancer 99, 431-433.
157. Sivertsen S., Berner A., Michael C.W., Bedrossian C. and Davidson B. (2006). Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions. Acta Cytol. 50, 603-607.
158. Slipicevic A., Øy G.F., Askildt I.C., Holth A., Hellesylt E., Flørenes V.A. and Davidson B. (2009). The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions. Hum. Pathol. 40, 527-537.
159. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R. and Shi Y. (2003). Mechanism of XIAPmediated inhibition of caspase-9. Mol. Cell 11, 519-527.
160. Soini Y. and Talvensaari-Mattila A. (2006). Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int. J. Gynecol. Pathol. 25, 330-335.
161. Song G., Ouyang G. and Bao S. (2005). The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. 9, 59-71.
162. Spannuth W.A., Sood A.K. and Coleman R.L. (2010). Farletuzumab in epithelial ovarian carcinoma. Expert Opin. Biol. Ther. 10, 431-437.
163. Sun C., Cai M., Gunasekera A.H., Meadows R.P., Wang H., Chen J., Zhang H., Wu W., Xu N., Ng S.C. and Fesik S.W. (1999). NMR structure and mutagenesis of the inhibitor-of-apoptosis protein XIAP. Nature 401, 818-822.
164. Suzuki M., Kato-Nakano M., Kawamoto S., Furuya A., Abe Y., Misaka H., Kimoto N., Nakamura K., Ohta S. and Ando H. (2009). Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100, 1623-1630.
165. Swisshelm K., Macek R. and Kubbies M. (2005). Role of claudins in tumorigenesis. Adv. Drug Deliv. Rev. 57, 919-928.
166. Takahashi R., Deveraux Q., Tamm I., Welsh K., Assa-Munt N., Salvesen G.S. and Reed J.C. (1998). A single BIR domain of XIAP sufficient for inhibiting caspases. J. Biol. Chem. 273, 7787-7790.
167. Takeda K., Stagg J., Yagita H., Okumura K. and Smyth M.J. (2007). Targeting death-inducing receptors in cancer therapy. Oncogene 26, 3745-3757.
168. Takei Y., Saga Y., Mizukami H., Takayama T., Ohwada M., Ozawa K. and Suzuki M. (2008). Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice. Mol. Cancer Ther. 7, 704-711.
169. Tang G., Minemoto Y., Dibling B., Purcell N.H., Li Z., Karin M. and Lin A. (2001). Inhibition of JNK activation through NF-kappaB target genes. Nature 414, 313-317.
170. Tassi R.A., Bignotti E., Falchetti M., Ravanini M., Calza S., Ravaggi A., Bandiera E., Facchetti F., Pecorelli S. and Santin A.D. (2008). Claudin-7 expression in human epithelial ovarian cancer. Int. J. Gynecol. Cancer 18, 1262-1271.
171. Taylor R.C., Cullen S.P. and Martin S.J. (2008). Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231-241.
172. Terauchi M., Kajiyama H., Yamashita M., Kato M., Tsukamoto H., Umezu T., Hosono S., Yamamoto E., Shibata K., Ino K., Nawa A., Nagasaka T. and Kikkawa F. (2007). Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin. Exp. Metastasis 24, 329-339.
173. Thériault B.L., Shepherd T.G., Mujoomdar M.L. and Nachtigal M.W. (2007). BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 28, 1153-1162.
174. Thiery J.P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2, 442-454.
175. Thompson F.H., Nelson M.A., Trent J.M., Guan X.Y., Liu Y., Yang J.M., Emerson J., Adair L., Wymer J., Balfour C., Massey K., Weinstein R., Alberts D.S. and Taetle R. (1996). Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet. Cytogenet. 87, 55-62.
176. Thompson J.E. and Thompson C.B. (2004). Putting the rap on Akt. J. Clin. Oncol. 22, 4217-4226.
177. Trinh X.B., van Dam P.A., Dirix L.Y., Vermeulen P.B. and Tjalma W.A. (2009). The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opin. Investig. Drugs. 18, 1885-1891.
178. Tsukita S., Furuse M. and Itoh M. (2001). Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2, 285-293.
179. Tsuruchi N., Kamura T., Tsukamoto N., Akazawa K., Saito T., Kaku T., To N. and Nakano H. (1993). Relationship between paraaortic lymph node involvement and intraperitoneal spread in patients with ovarian cancer--a multivariate analysis. Gynecol. Oncol. 49, 51-55.
180. Tuhkanen H., Soini Y., Kosma V.M., Anttila M., Sironen R., Hämäläinen K., Kukkonen L., Virtanen I. and Mannermaa A. (2009). Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression. BMC Cancer 9, 289.
181. van der Wal J.B. and Jeekel J. (2007). Biology of the peritoneum in normal homeostasis and after surgical trauma. Colorectal Dis. 9 Suppl 2, 9-13.
182. Van Itallie C.M. and Anderson J.M. (2006). Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 68, 403-429.
183. Vermes I., Haanen C. and Reutelingsperger C. (2000). Flow cytometry of apoptotic cell death. J. Immunol. Methods 243, 167-190.
184. Vernon A.E. and LaBonne C. (2004). Tumor metastasis: a new twist on epithelial-mesenchymal transitions. Curr. Biol. 14, R719-721.
185. Vivanco I. and Sawyers C. (2002). The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat. Rev. Cancer 2, 489-501.
186. Wajant H., Pfizenmaier K. and Scheurich P. (2003). Tumor necrosis factor signaling. Cell Death Differ. 10, 45-65.
187. Walker G., MacLeod K., Williams A.R., Cameron D.A., Smyth J.F. and Langdon S.P. (2007). Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin. Cancer Res. 13, 1438-1444.
188. Wang C.Y., Guttridge D.C., Mayo M.W., Baldwin A.S. Jr (1999). NFkappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell Biol. 19, 5923-5929.
189. Wang X. (2001). The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933.
190. Wang X., Ling M.T., Guan X.Y., Tsao S.W., Cheung H.W., Lee D.T. and Wong Y.C. (2004). Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23, 474-482.
191. Wiley A., Katsaros D., Fracchioli S. and Yu H. (2006). Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16, 210-218.
192. Witowski J., Ksiazek K. and Jorres A. (2008). New insights into the biology of peritoneal mesothelial cells: the roles of epithelial-tomesenchymal transition and cellular senescence. Nephron Exp. Nephrol. 108, e69-73.
193. Woenckhaus J., Steger K., Sturm K., Münstedt K., Franke F.E. and Fenic I. (2007). Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer. Virchows Arch. 450, 387-395.
194. Xiao C.W., Yan X., Li Y., Reddy S.A. and Tsang B.K. (2003). Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology 144, 623-630.
195. Yang H., Kong W., He L., Zhao J.J., O'Donnell J.D., Wang J., Wenham R.M., Coppola D., Kruk P.A., Nicosia S.V. and Cheng J.Q. (2008). MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433.
196. Yang X., Zheng F., Xing H., Gao Q., Wei W., Lu Y., Wang S., Zhou J., Hu W. and Ma D. (2004). Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J. Cancer Res. Clin. Oncol. 130, 423-428.
197. Yang Z., Rayala S., Nguyen D., Vadlamudi R.K., Chen S. and Kumar R. (2005). Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res. 65, 3179-3184.
198. Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S. and Workman P. (2008). Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr. Opin. Pharmacol. 8, 393-412.
199. Yokoyama K., Kamata N., Hayashi E., Hoteiya T., Ueda N., Fujimoto R. and Nagayama M. (2001). Reverse correlation of E-cadherin and snail expression in oral squamous cell carcinoma cells in vitro. Oral Oncol. 37, 65-71.
200. Yokoyama K., Kamata N., Fujimoto R., Tsutsumi S., Tomonari M., Taki M., Hosokawa H. and Nagayama M. (2003). Increased invasion and matrix metalloproteinase-2 expression by Snail-induced mesenchymal transition in squamous cell carcinomas. Int. J. Oncol. 22, 891-898.
201. Yoshida J., Horiuchi A., Kikuchi N., Hayashi A., Osada R., Ohira S., Shiozawa T. and Konishi I. (2009). Changes in the expression of Ecadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 42, 82-91.
202. Yuan X., Lin X., Manorek G., Kanatani I., Cheung L.H., Rosenblum M.G. and Howell S.B. (2009). Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol. Cancer Ther. 8, 1906-1915.
203. Yuan Y., Nymoen D.A., Dong H.P., Bjørang O., Shih I-M., Low P.S., Trope' C.G. and Davidson B. (2009). Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum. Pathol. 40, 1453-1460.
204. Yung S. and Chan T.M. (2009). Intrinsic cells: mesothelial cells--central players in regulating inflammation and resolution. Perit. Dial. Int. 29 Suppl 2, S21-7.
205. Zhu Y., Brannstrom M., Janson P.O. and Sundfeldt K. (2006). Differences in expression patterns of the tight junction proteins, claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int. J. Cancer 118, 1884-1891.